Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.

P <0.1 was considered marginally significant. 2.6 Role of funders Funders had no role in study design, data collection, data analyses, interpretation, or writing of report. 3 Results 3.1 TP53 missense but not nonsense mutations are associated with increased PD-L1 levels PDL1 expression have been widely taken as a reliable biomarker in guiding ICIs administration, and TP53 mutant status in LUAD was reported to be associated with higher PD-L1 expression level.

also in 26,082 other papers